Applied dna partners with cornell university college of veterinary medicine to accelerate development of veterinary vaccine platform targeting diseases that impact high-value animals

Agreement focuses on the accelerated development of lnp-encapsulated lineadna™ vaccines to eliminate the use of plasmid dna and reduce the dependence on extreme cold chains of today's mrna vaccines stony brook, ny and ithaca, ny / accesswire / september 14, 2023 / applied dna sciences, inc. (nasdaq:apdn) (‘applied dna' or the "company"), a leader in polymerase chain reaction ("pcr")-based technologies, and the cornell university college of veterinary medicine ("cucvm") today announced the signing of a sponsored research agreement (the "agreement") for a translational research study to accelerate the development and optimization of the company's lineadna™-lipid nano particle (lnp)-based veterinary vaccine platform (the "vaccine platform") for veterinary diseases. cucvm is a world-ranked u.s. university for veterinary medical education, animal medicine, and biomedical research.
APDN Ratings Summary
APDN Quant Ranking